Compare FMN & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMN | CSBR |
|---|---|---|
| Founded | 2002 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.9M | 90.0M |
| IPO Year | N/A | 1986 |
| Metric | FMN | CSBR |
|---|---|---|
| Price | $11.10 | $7.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 22.8K | 9.4K |
| Earning Date | 01-01-0001 | 12-15-2025 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | ★ $56,878,000.00 |
| Revenue This Year | N/A | $7.31 |
| Revenue Next Year | N/A | $12.01 |
| P/E Ratio | ★ N/A | $31.49 |
| Revenue Growth | N/A | ★ 10.11 |
| 52 Week Low | $9.09 | $4.61 |
| 52 Week High | $11.31 | $11.99 |
| Indicator | FMN | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 45.28 | 66.26 |
| Support Level | $11.06 | $6.22 |
| Resistance Level | $11.24 | $6.43 |
| Average True Range (ATR) | 0.07 | 0.29 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 33.33 | 67.92 |
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.